Adelaide Research & Scholarship: Search

Search

Results 1-10 of 19 (Search time: 0.011 seconds).

previous
1
2
next

Item hits:

Preview	Issue Date	Title	Author(s)
	2013	STAT5 is a critical component of the time-dependent sensitivity of CML cells to TKI treatment in a BCR-ABL-dependent, but JAK2-independent manner	Schafranek, L.; Nievergall, E.; Powell, J.; Hiwase, D.; White, D.; Hughes, T.; Leclercq, T.
	2013	PCR-mediated recombination can lead to artificial chimera formation, which may pose as BCR-ABL1 compound mutations	Parker, W.; Phillis, S.; Yeung, D.; Hughes, T.; Scott, H.; Branford, S.; 55th American Society of Hematology Annual Meeting and Exhibition (7 Dec 2013 - 10 Dec 2013 : New Orleans, Louisiana)
	2013	BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance	Parker, W.; Yeoman, A.; Jamison, B.; Yeung, D.; Scott, H.; Hughes, T.; Branford, S.
	2013	Signalling by the βc family of cytokines	Hercus, T.; Dhagat, U.; Kan, W.; Broughton, S.; Nero, T.; Perugini, M.; Sandow, J.; D'Andrea, R.; Ekert, P.; Hughes, T.; Parker, M.; Lopez, A.
	2013	Which TKI? An embarrassment of riches for chronic myeloid leukemia patients	Hughes, T.; White, D.
	2013	Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia	Stein, A.; Martinelli, G.; Hughes, T.; Muller, M.; Beppu, L.; Gottardi, E.; Branford, S.; Soverini, S.; Woodman, R.; Hochhaus, A.; Kim, D.; Saglio, G.; Radich, J.
	2013	Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML	Branford, S.; Yeung, D.; Ross, D.; Prime, J.; Field, C.; Altamura, H.; Yeoman, A.; Georgievski, J.; Jamison, B.; Phillis, S.; Sullivan, B.; Briggs, N.; Hertzberg, M.; Seymour, J.; Reynolds, J.; Hughes, T.
	2013	Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study	Ross, D.; Branford, S.; Seymour, J.; Schwarer, A.; Arthur, C.; Yeung, D.; Dang, P.; Goyne, J.; Slader, C.; Filshie, R.; Mills, A.; Vaz de Melo, J.; White, D.; Grigg, A.; Hughes, T.
	2013	Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase	Hochhaus, A.; Saglio, G.; Larson, R.; Kim, D.; Etienne, G.; Rosti, G.; De Souza, C.; Kurokawa, M.; Kalaycio, M.; Hoenekopp, A.; Fan, X.; Shou, Y.; Kantarjian, H.; Hughes, T.
	2013	European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013	Baccarani, M.; Deininger, M.; Rosti, G.; Hochhaus, A.; Soverini, S.; Apperley, J.; Cervantes, F.; Clark, R.; Cortes, J.; Guilhot, F.; Hansen-Hjorth, H.; Hughes, T.; Kantarjian, H.; Kim, D.; Larson, R.; Lipton, J.; Mahon, F.; Martinelli, G.; Mayer, J.; Muller, M.; et al.